Compare Wockhardt with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs GSK PHARMA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT GSK PHARMA WOCKHARDT/
GSK PHARMA
 
P/E (TTM) x -87.2 51.3 - View Chart
P/BV x 1.9 11.6 16.7% View Chart
Dividend Yield % 0.0 1.4 0.1%  

Financials

 WOCKHARDT   GSK PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
GSK PHARMA
Mar-19
WOCKHARDT/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0123,595 28.2%   
Low Rs5321,253 42.4%   
Sales per share (Unadj.) Rs355.9184.7 192.7%  
Earnings per share (Unadj.) Rs-60.326.3 -229.3%  
Cash flow per share (Unadj.) Rs-46.829.2 -160.4%  
Dividends per share (Unadj.) Rs0.0120.00 0.1%  
Dividend yield (eoy) %00.8 0.2%  
Book value per share (Unadj.) Rs257.8126.3 204.1%  
Shares outstanding (eoy) m110.63169.40 65.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.213.1 16.5%   
Avg P/E ratio x-12.892.2 -13.9%  
P/CF ratio (eoy) x-16.583.1 -19.9%  
Price / Book Value ratio x3.019.2 15.6%  
Dividend payout %076.1 -0.0%   
Avg Mkt Cap Rs m85,379410,626 20.8%   
No. of employees `0006.35.0 126.1%   
Total wages/salary Rs m9,3715,372 174.4%   
Avg. sales/employee Rs Th6,295.06,306.7 99.8%   
Avg. wages/employee Rs Th1,498.31,083.1 138.3%   
Avg. net profit/employee Rs Th-1,066.3898.0 -118.7%   
INCOME DATA
Net Sales Rs m39,36931,281 125.9%  
Other income Rs m1,2021,023 117.5%   
Total revenues Rs m40,57132,304 125.6%   
Gross profit Rs m186,009 0.3%  
Depreciation Rs m1,495486 307.7%   
Interest Rs m2,5556 42,581.7%   
Profit before tax Rs m-2,8306,540 -43.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582287 -1,248.0%   
Tax Rs m2572,373 10.8%   
Profit after tax Rs m-6,6694,454 -149.7%  
Gross profit margin %019.2 0.2%  
Effective tax rate %-9.136.3 -25.0%   
Net profit margin %-16.914.2 -119.0%  
BALANCE SHEET DATA
Current assets Rs m33,79620,061 168.5%   
Current liabilities Rs m26,91714,543 185.1%   
Net working cap to sales %17.517.6 99.0%  
Current ratio x1.31.4 91.0%  
Inventory Days Days7957 139.8%  
Debtors Days Days8914 634.6%  
Net fixed assets Rs m39,66414,343 276.5%   
Share capital Rs m5531,694 32.7%   
"Free" reserves Rs m27,96819,704 141.9%   
Net worth Rs m28,52221,398 133.3%   
Long term debt Rs m21,7312 1,086,555.0%   
Total assets Rs m81,62039,113 208.7%  
Interest coverage x-0.11,091.0 -0.0%   
Debt to equity ratio x0.80 815,189.2%  
Sales to assets ratio x0.50.8 60.3%   
Return on assets %-5.011.4 -44.2%  
Return on equity %-23.420.8 -112.3%  
Return on capital %-7.731.9 -24.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,807534 1,836.5%   
Fx outflow Rs m1,7897,091 25.2%   
Net fx Rs m8,019-6,557 -122.3%   
CASH FLOW
From Operations Rs m6843,994 17.1%  
From Investments Rs m6,302-1,433 -439.7%  
From Financial Activity Rs m-7,695-3,584 214.7%  
Net Cashflow Rs m-664-1,023 64.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 2.3 10.2 22.5%  
FIIs % 7.7 23.8 32.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 15.4 100.0%  
Shareholders   67,757 102,036 66.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare WOCKHARDT With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street, MTAR Technologies IPO, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed a sharp sell-off on Friday and ended deep in the red.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Feb 26, 2021 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT 8-QTR ANALYSIS

COMPARE WOCKHARDT WITH

MARKET STATS